BR112021009801A2 - Uso de derivado da glutarimida para superar resistência a esteroide e tratar doenças associadas, com a sinalização aberrante do interferon gama - Google Patents
Uso de derivado da glutarimida para superar resistência a esteroide e tratar doenças associadas, com a sinalização aberrante do interferon gamaInfo
- Publication number
- BR112021009801A2 BR112021009801A2 BR112021009801A BR112021009801A BR112021009801A2 BR 112021009801 A2 BR112021009801 A2 BR 112021009801A2 BR 112021009801 A BR112021009801 A BR 112021009801A BR 112021009801 A BR112021009801 A BR 112021009801A BR 112021009801 A2 BR112021009801 A2 BR 112021009801A2
- Authority
- BR
- Brazil
- Prior art keywords
- interferon gamma
- diseases associated
- gamma signaling
- treat diseases
- overcome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018141291A RU2712281C1 (ru) | 2018-11-23 | 2018-11-23 | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| PCT/RU2019/050225 WO2020106191A1 (ru) | 2018-11-23 | 2019-11-22 | Производное глутаримида для преодоления резистентности к стероидам |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021009801A2 true BR112021009801A2 (pt) | 2022-03-03 |
Family
ID=69624712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021009801A BR112021009801A2 (pt) | 2018-11-23 | 2019-11-22 | Uso de derivado da glutarimida para superar resistência a esteroide e tratar doenças associadas, com a sinalização aberrante do interferon gama |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220362230A1 (https=) |
| EP (2) | EP4218758A3 (https=) |
| JP (2) | JP2022508167A (https=) |
| KR (2) | KR20220162821A (https=) |
| CN (2) | CN114652721A (https=) |
| AU (2) | AU2019384626A1 (https=) |
| BR (1) | BR112021009801A2 (https=) |
| CA (1) | CA3120882A1 (https=) |
| CL (2) | CL2021001316A1 (https=) |
| EA (1) | EA201992646A1 (https=) |
| GE (4) | GEAP202215712A (https=) |
| IL (2) | IL297533A (https=) |
| MD (2) | MD4844C1 (https=) |
| MX (2) | MX2021006032A (https=) |
| MY (1) | MY209416A (https=) |
| PH (1) | PH12021551152A1 (https=) |
| RU (1) | RU2712281C1 (https=) |
| WO (1) | WO2020106191A1 (https=) |
| ZA (2) | ZA202104247B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023177329A1 (ru) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями |
| WO2023191666A1 (ru) * | 2022-03-29 | 2023-10-05 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9111874U1 (de) * | 1991-09-23 | 1991-11-21 | Haag, Richard, 7181 Satteldorf | Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten |
| EP0625045A4 (en) * | 1992-02-07 | 1995-01-18 | Albert M Kligman | METHOD FOR TREATING FLAMMABLE DERMATOS. |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| US20090087425A1 (en) | 2007-08-10 | 2009-04-02 | Topigen Pharmaceuticals Inc. | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| RU2404792C1 (ru) * | 2009-05-20 | 2010-11-27 | Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" | Средство для преодоления стероидной резистентности |
| US20140112913A1 (en) * | 2011-02-10 | 2014-04-24 | Genqual Corporation | Methods of prognosing and administering treatment for inflammatory disorders |
| JP2014511181A (ja) | 2011-02-24 | 2014-05-15 | ファーマキシス リミテッド | キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤 |
| CN110128406B (zh) * | 2013-04-12 | 2021-08-27 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
| RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
-
2018
- 2018-11-23 RU RU2018141291A patent/RU2712281C1/ru active
-
2019
- 2019-11-22 US US17/296,539 patent/US20220362230A1/en not_active Abandoned
- 2019-11-22 BR BR112021009801A patent/BR112021009801A2/pt not_active IP Right Cessation
- 2019-11-22 GE GEAP202215712A patent/GEAP202215712A/en unknown
- 2019-11-22 IL IL297533A patent/IL297533A/en unknown
- 2019-11-22 CN CN202210260820.9A patent/CN114652721A/zh active Pending
- 2019-11-22 EA EA201992646A patent/EA201992646A1/ru unknown
- 2019-11-22 GE GEAP201915712A patent/GEP20237467B/en unknown
- 2019-11-22 MD MDA20210050A patent/MD4844C1/ro active IP Right Grant
- 2019-11-22 GE GEAP202415619A patent/GEAP202415619A/en unknown
- 2019-11-22 CN CN201980076564.4A patent/CN113164464A/zh active Pending
- 2019-11-22 KR KR1020227040632A patent/KR20220162821A/ko not_active Ceased
- 2019-11-22 CA CA3120882A patent/CA3120882A1/en active Pending
- 2019-11-22 GE GEAP201915619A patent/GEP20247643B/en unknown
- 2019-11-22 AU AU2019384626A patent/AU2019384626A1/en not_active Abandoned
- 2019-11-22 KR KR1020217019084A patent/KR20210095652A/ko not_active Withdrawn
- 2019-11-22 WO PCT/RU2019/050225 patent/WO2020106191A1/ru not_active Ceased
- 2019-11-22 MX MX2021006032A patent/MX2021006032A/es unknown
- 2019-11-22 JP JP2021528866A patent/JP2022508167A/ja active Pending
- 2019-11-22 MY MYPI2021002768A patent/MY209416A/en unknown
- 2019-11-22 MD MDA20210032A patent/MD4851C1/ro active IP Right Grant
- 2019-11-22 EP EP22210617.1A patent/EP4218758A3/en active Pending
- 2019-11-22 EP EP19886166.8A patent/EP3884945A4/en not_active Withdrawn
-
2021
- 2021-05-19 CL CL2021001316A patent/CL2021001316A1/es unknown
- 2021-05-20 PH PH12021551152A patent/PH12021551152A1/en unknown
- 2021-05-20 IL IL283317A patent/IL283317A/en unknown
- 2021-05-21 MX MX2022013503A patent/MX2022013503A/es unknown
- 2021-06-21 ZA ZA2021/04247A patent/ZA202104247B/en unknown
-
2022
- 2022-03-21 CL CL2022000683A patent/CL2022000683A1/es unknown
- 2022-09-21 ZA ZA2022/10444A patent/ZA202210444B/en unknown
- 2022-10-21 AU AU2022256212A patent/AU2022256212B2/en active Active
- 2022-11-17 JP JP2022184210A patent/JP7518997B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aziz et al. | Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies | |
| Astulla et al. | Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities | |
| SA521421619B1 (ar) | صيغ عقار مقاومة للكحول | |
| MX2022000709A (es) | Regimenes de tratamiento con dexmedetomidina no sedante. | |
| EA201800499A1 (ru) | Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| CL2010001467A1 (es) | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. | |
| BR112021024632A2 (pt) | Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea | |
| BR112021009801A2 (pt) | Uso de derivado da glutarimida para superar resistência a esteroide e tratar doenças associadas, com a sinalização aberrante do interferon gama | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| WO2021099838A9 (en) | Adenosine receptor antagonist compounds | |
| BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| PH12018502703A1 (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| MA39524A1 (fr) | 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs | |
| Karia et al. | Tiapride for the treatment of auditory hallucinations in schizophrenia | |
| GEAP202416375A (en) | Pro drugs of pde10 compounds | |
| BR112012000410B8 (pt) | uso de benzidamina ou dos sais de adição de ácido, e, composição farmacêutica | |
| BR112022006560A2 (pt) | Moduladores de atf6 e usos dos mesmos | |
| Gaensler et al. | ACTIVITY OF SOME NEWER SPASMOLYTIC AGENTS ON THE BILIARY TRACT OF MAN: A Comparative Study of Isopropyl-Norepinephrine, Adiphenine Hydrochloride, Methylamino-iso-octene and Khellin | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| Yilmaz | Albendazole/cetirizine | |
| Sharma et al. | Erectile dysfunction in male psychiatric patients. | |
| UK | Configuration of services: service design: Cerebral palsy in adults | |
| MX2022006537A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ''CHEMIMMUNE THERAPEUTICS'' LIMITED LIABILITY COMPANY (RU) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2802 DE 17/09/2024. |